Andrew Lee, Ph.D.

Andrew Lee is a Director at Northpond Ventures, specializing in biomanufacturing, life science R&D solutions, and environmental sciences. He is a board director at Culture Biosciences, Slingshot Biosciences, and EnPlusOne Biosciences as well as a board observer at 64x Bio, Ansa Biotechnologies, Refeyn, Sherlock Biosciences, and Sound Agriculture. Previously, Andrew was an Associate at Booz Allen Hamilton working in the Biological Technologies Office at the Defense Advanced Research Projects Agency (DARPA), where he worked on the development and management of a high-risk, high-reward research funding portfolio in gene editing and synthetic biology. Earlier, he worked at Sangamo Biosciences (now Sangamo Therapeutics) and the Joint BioEnergy Institute. Andrew earned a Ph.D. in Microbiology and Immunology from Columbia University. He received a B.A. with honors in Molecular and Cell Biology, with an emphasis in biochemistry and molecular biology, from The University of California, Berkeley.